Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational ...
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.
Becker's Hospital Review29d
FDA grants fast-track status to combination influenza and COVID-19 vaccine candidates
The FDA has granted fast ... from both influenza and COVID-19, according to a Dec. 16 AJMC report. These vaccine candidates combine the flu vaccine with the Novavax COVID-19 vaccine, offering ...
Nasdaq1mon
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.